September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.

September 21, 2009 - Toshiba America Medical Systems Inc. introduced Low-Contrast Imaging (LCI) for Toshiba’s Infinix-i systems with mid (12 x12-inch) flat and large (12 x16-inch) flat-panel detectors (FPD), and will demonstrate its low-contrast imaging capabilities at this year’s Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco, Sept. 21 - Sept.

September 21, 2009 — Minnow Medical recently announced it will be presenting interim clinical data regarding a novel technology to treat Peripheral Artery Disease (PAD) on Monday, Sept. 21. The presentation, led by James R. Margolis will take place at 11:58 a.m. in room 133.

September 18, 2009 - A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia in a single examination, giving a better indication of clinically significant coronary artery disease, said a report appears in the September 15 issue of the Journa

September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast symposium starting at 6:30 a.m. Wedensday, Sept. 23 in room 121 at the Moscone Center in San Francisco.

September 18, 2009 – Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation (AF) using a visually-guided laser balloon catheter.

September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its PLATINUM clinical program, a global, randomized, pivotal controlled trial designed to support FDA and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum-chromium PROMUS Element Everolimus-Eluting Coronary Stent System.

September 18, 2009 – The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, Sept. 21-25, in San Francisco.


When vessels are stretched and ripped via angioplasty balloon expansion, the exposed soft muscle tissue can lead to the proliferation of scar tissue (neointimal hyperplasia) that can reocclude the vessel. Drug-eluting stents (DES) were introduced in 2003 to overcome this issue with anti-proliferative drugs, the same as used to prevent cellular growth in cancerous tumors.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now